Dr. Andrew D. Leavitt, MD

Dr. Leavitt practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Leavitt's NPI, 1952343113, was assigned on June 12, 2006. Dr. Leavitt graduated from Harvard Medical School in 1984. Dr. Leavitt holds California license G65749.

Dr. Leavitt's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Leavitt's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Leavitt is also affiliated with MarinHealth Medical Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Leavitt to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leavitt practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Leavitt's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Leavitt is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Leavitt's licenses on file in 2 states: California and Michigan.

Dmand AI lists acute kidney failure, arterial blot clot /embolism, chronic anemia, chronic embolism thrombosis, deep vein thrombosis (DVT), menopause, purpura and thrombocytopenia and varicose veins among the conditions Dr. Leavitt treats.

CMS data shows 579 Medicare services from Dr. Leavitt across 9 procedure codes in 2024, for 357 Medicare patients. Medicare paid $48,928 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 357 Medicare patients who saw Dr. Leavitt in 2024. The largest group is 65 to 74, with 146 patients. 68% of them have high blood pressure, and 67% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leavitt's median patient age at 55, with 58% women.

In 2024, Dr. Leavitt wrote 334 Medicare Part D claims for 77 patients. 26% of them were for generic drugs. CMS names the drug for 302 of them, across 7 drugs with 11 or more claims each, at $818,329 in total drug cost. In 2023, CMS named 230 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Leavitt for performance year 2024, reported as part of a group. Dr. Leavitt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leavitt as offering telehealth.

Dmand AI links 84 papers to Dr. Leavitt, published from 2002 to 2025. 2022 was the busiest year, with 8. The most frequent topics are Hemophilia A, Hemorrhage and Genetic Vectors. Dr. Leavitt has published most often in Blood. Dr. Leavitt's most frequent co-authors are Nigel S. Key, MD, Steven W. Pipe, MD and Doris Voy Kan Quon, MD.

Dmand AI links Dr. Leavitt to 2 clinical trials. Conditions studied include Hemophilia B and Hemophilia A.

CMS Open Payments shows 100 general payments to Dr. Leavitt from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. BioMarin Pharmaceutical Inc. paid the most, $68,738. It also lists 25 research payments totaling $21,100 from 2020 to 2025.

Dmand AI lists 1 award for Dr. Leavitt.

Dr. Leavitt graduated from Harvard Medical School in 1984.

Dr. Leavitt is in network with 7 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.